122 related articles for article (PubMed ID: 698557)
1. HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine.
Chadwick RG; Bassendine MF; Crawford EM; Thomas HC; Sherlock S
Br Med J; 1978 Aug; 2(6136):531-3. PubMed ID: 698557
[TBL] [Abstract][Full Text] [Related]
2. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study.
Bassendine MF; Chadwick RG; Salmeron J; Shipton U; Thomas HC; Sherlock S
Gastroenterology; 1981 May; 80(5 pt 1):1016-22. PubMed ID: 7009310
[TBL] [Abstract][Full Text] [Related]
3. Relationship between HBV-specific DNA polymerase and HBe antigen/antibody system in chronic HBV infection: factors determining selection of patients and outcome of antiviral therapy.
Craxi A; Weller IV; Bassendine MF; Fowler MJ; Monjardino J; Thomas HC; Sherlock S
Gut; 1983 Feb; 24(2):143-7. PubMed ID: 6852624
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the antiviral effects of adenine arabinoside on chronic HBV infection.
Watanabe S; Saito S; Yoshikawa A; Shibayama T; Kamimura T; Suzuki S; Ischida F
Hepatogastroenterology; 1982 Jun; 29(3):102-5. PubMed ID: 7106692
[TBL] [Abstract][Full Text] [Related]
5. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B.
Scullard GH; Smith CI; Merigan TC; Robinson WS; Gregory PB
Gastroenterology; 1981 Dec; 81(6):987-91. PubMed ID: 7286593
[TBL] [Abstract][Full Text] [Related]
6. Full and empty Dane particles in chronic hepatitis B virus infection: relation to hepatitis B e antigen and presence of liver damage.
Alberti A; Diana S; Scullard GH; Eddleston WF; Williams R
Gastroenterology; 1978 Nov; 75(5):869-74. PubMed ID: 700329
[TBL] [Abstract][Full Text] [Related]
7. Dane particles and associated DNA-polymerase activity in saliva of chronic hepatitis B carriers.
Macaya G; Visoná KA; Villarejos VM
J Med Virol; 1979; 4(4):291-301. PubMed ID: 541682
[TBL] [Abstract][Full Text] [Related]
8. Effects of human leucocyte interferon on hepatitis B virus replication and immune responses in patients with chronic hepatitis B infection.
Scullard GH; Alberti A; Wansbrough-Jones MH; Howard CR; Eddleston AL; Zuckerman AJ; Cantell K; Williams R
J Clin Lab Immunol; 1979 Feb; 1(4):277-82. PubMed ID: 501726
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP).
Weller IV; Bassendine MF; Craxi A; Fowler MJ; Monjardino J; Thomas HC; Sherlock S
Gut; 1982 Sep; 23(9):717-23. PubMed ID: 6179819
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological response of HBsAg-positive chronic active hepatitis to adenine arabinoside: lack of correlation with DNA polymerase response.
Liaw YF; Lin DY; Chen TJ; Chu CM; Sheen IS
Infection; 1984; 12(4):248-50. PubMed ID: 6490167
[TBL] [Abstract][Full Text] [Related]
11. Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside.
Scullard GH; Andres LL; Greenberg HB; Smith JL; Sawhney VK; Neal EA; Mahal AS; Popper H; Merigan TC; Robinson WS; Gregory PB
Hepatology; 1981; 1(3):228-32. PubMed ID: 6169615
[No Abstract] [Full Text] [Related]
12. Effect of vidarabine on chronic hepatitis B virus infection.
Pollard RB; Smith JL; Neal A; Gregory PB; Merigan TC; Robinson WS
JAMA; 1978 Apr; 239(16):1648-50. PubMed ID: 633577
[No Abstract] [Full Text] [Related]
13. Infectivity markers in HBsAg chronic carriers and intrafamilial spread of hepatitis B virus infection.
Pastore G; Dentico P; Angarano G; Lapedota E; Schiraldi O
Hepatogastroenterology; 1981 Feb; 28(1):20-2. PubMed ID: 7216135
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of a low dosage of human leukocyte interferon on chronic hepatitis B virus infection.
Matsumura N; Yoshikawa T; Kondo M; Kawakami H; Kishida T
Digestion; 1983; 26(4):205-12. PubMed ID: 6873506
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of quinacrine for the treatment of HBsAg-positive chronic hepatitis.
Bodenheimer HC; Schaffner F; Vernace S; Hirschman SZ; Goldberg JD; Chalmers T
Hepatology; 1983; 3(6):936-8. PubMed ID: 6354904
[TBL] [Abstract][Full Text] [Related]
16. The relationship of hepatitis B e antigen, DNA polymerase activity, and titer of hepatitis B surface antigen with ongoing liver injury in chronic hepatitis B virus infection.
Perrillo R; Campbell C; Wellinghoff W; Gelb L
Am J Gastroenterol; 1982 Jul; 77(7):445-9. PubMed ID: 7091131
[TBL] [Abstract][Full Text] [Related]
17. Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
Weller IV; Lok AS; Mindel A; Karayiannis P; Galpin S; Monjardino J; Sherlock S; Thomas HC
Gut; 1985 Jul; 26(7):745-51. PubMed ID: 2410328
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of the determination of DNA polymerase activity of hepatitis B virus in chronic HBsAg carriers].
Carreño García V; Porres Cubero JC; Mora Pérez I; Hernańdez Guío C
Rev Clin Esp; 1984 Aug 15-31; 174(3-4):75-7. PubMed ID: 6515078
[No Abstract] [Full Text] [Related]
19. e-Antigen: a link between immune response and infectivity in hepatitis B?
Turner GC; Green HT; Blundell VD
J Hyg (Lond); 1978 Dec; 81(3):405-14. PubMed ID: 731022
[TBL] [Abstract][Full Text] [Related]
20. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy.
Marcellin P; Martinot-Peignoux M; Loriot MA; Giostra E; Boyer N; Thiers V; Benhamou JP
Ann Intern Med; 1990 Feb; 112(3):227-8. PubMed ID: 2297196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
